Koyfin Home > Directory > Health Care > Arbutus Biopharma Cp > Gross Margin

Arbutus Biopharma Cp Gross Margin Chart (ABUS)

Arbutus Biopharma Cp annual/quarterly Gross Margin from 2010 to 2018. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Arbutus Biopharma Cp Gross Margin for the quarter ending December 12, 2018 was $2,970m a 104.22% increase of 3,096m year over year
  • Arbutus Biopharma Cp Gross Margin for the last 12 months ending December 12, 2018 was $100m a 368.78% increase of 369m year over year
  • Arbutus Biopharma Cp Annual Gross Margin for 2018 was $100m a 190.19% increase of 190m from 2017
  • Arbutus Biopharma Cp Annual Gross Margin for 2015 was $-90m a -76.19% increase of 69m from 2014
  • Arbutus Biopharma Cp Annual Gross Margin for 2014 was $-159m a 75.61% decrease of -120m from 2013
Other Margins & Efficiency Metrics:
  • Arbutus Biopharma Cp EBITDA Margin for the quarter ending September 09, 2017 was $-142m a -71.85% increase of 102m year over year
  • Arbutus Biopharma Cp Return on Capital % for the quarter ending December 12, 2018 was -19.07 a -3.10% increase of 0.59 year over year
  • Arbutus Biopharma Cp Return on Equity % for the quarter ending December 12, 2018 was -35.22 a 4.57% decrease of -1.61 year over year
View Chart On Koyfin

Quarterly ABUS Gross Margin Data

12/2018$2,970m
09/2018$100m
06/2018$1,221m
09/2017$-125m
12/2015$-6m
09/2015$-268m
06/2015$-182m
03/2015$-125m
12/2014$-174m
09/2014$-113m

Annual ABUS Gross Margin Data

2018$100m
2015$-90m
2014$-159m
2013$-39m
2012$-28m
2011$-20m
2010$-4m
2009$-23m